ライフサイエンスコーパス: procedural complication

1 roblems precluding outpatient care, or had a procedural complication.

2 n, unstable angina hospitalization, or major procedural complication.

3 The primary safety outcome was any procedural complication.

4 ospitalization for unstable angina, or major procedural complication.

5 to model the calculated risk score and major procedural complications.

6 There were no procedural complications.

7 ocardial infarction (MI) unrelated to direct procedural complications.

8 atients, and appeared to be related to acute procedural complications.

9 We had three cases of peri-procedural complications.

10 atient comorbidities, type of procedure, and procedural complications.

11 evaluate the association between ICI use and procedural complications.

12 ppression of PVCs and presence or absence of procedural complications.

13 here were 3 (1.3%) major and 13 (5.4%) minor procedural complications.

14 al artery spasm, radial artery occlusion, or procedural complications.

15 ular risk, and communication about potential procedural complications.

16 R) has gained over time a major reduction in procedural complications.

17 is low, even in the presence of low rates of procedural complications.

18 outcomes included 30-day major endpoints and procedural complications.

19 aiming for a high volume may help to reduce procedural complications.

20 s in procedural success, procedure time, and procedural complications.

21 malignant causes of biliary obstruction and procedural complications.

22 and rehospitalization, but similar risks of procedural complications.

23 r adverse cardiovascular events (MACEs), and procedural complications.

24 on imaging and clinic reports identified any procedural complications.

25 undergoing TA-TAVR or presenting with major procedural complications.

26 composite of in-hospital mortality and peri-procedural complications.

27 doscopist must have the capability to manage procedural complications.

28 s coronary intervention (PCI) are related to procedural complications.

29 stent thrombosis (ST) or restenosis and peri-procedural complications.

30 was achieved in seven patients with no major procedural complications.

31 ring surgical removal, there were no serious procedural complications.

32 For safety outcomes, there were no procedural complications (0%).

33 The category next in frequency was procedural complications (1.76 claims per 1000 person-ye

34 Patient drive time (as a proxy for access), procedural complications, 1-year mortality, myocardial i

35 disease (22.2%), cardiac conditions (11.4%), procedural complications (11.0%), and endocrine issues (

36 (23.7%), 99 missed diagnoses (30.1%), and 54 procedural complications (16.4%); some cases were in mor

37 result in significantly more major and minor procedural complications (18.0% vs. 3.1%, p = 0.0004), m

38 Procedural complications (2.3% versus 10.8%; odds ratio,

39 associated with: 1) somewhat increased major procedural complications, 2) significantly higher freque

40 The most common cause of readmission was procedural complications (28.0%), followed by sepsis (8.

41 The rates of procedural complications (5.8%) and acute kidney injury

42 There were no major procedural complications; 6 patients underwent subsequen

43 There were two procedural complications: a vasovagal episode requiring

44 oscopy-guided angiography) sclerotherapy and procedural complications (according to Clavien-Dindo cla

45 After adjustment for age and comorbidities, procedural complications (adjusted odds ratio [aOR]: 4.0

46 lassification, and quality-of-life impact of procedural complications affected results.

47 There were four immediate procedural complications: Air emboli occurred in two pat

48 Procedural complications also tended to be lower among t

49 describes in-hospital mortality following a procedural complication and has been adopted as a qualit

50 Secondary end points included incidence of procedural complications and 1-year major adverse cardia

51 We examined procedural complications and 30-day mortality and major

52 aging and clinical reports were reviewed for procedural complications and assessment of the long-term

53 PCI and post-PCI characteristics, including procedural complications and discharge characteristics,

54 There were no procedural complications and four 30-day major adverse e

55 tions of SVGs have been associated with more procedural complications and higher restenosis rates com

56 s study is to quantify the incidence of post-procedural complications and identify patients at higher

57 ns who implant more ICDs have lower rates of procedural complications and in-hospital mortality, inde

58 Procedural complications and limb revascularization rate

59 logist were associated with a higher risk of procedural complications and lower likelihood of receivi

60 tral ViR was associated with higher rates of procedural complications and mid-term mortality compared

61 ation were associated with increased risk of procedural complications and midterm mortality.

62 No procedural complications and no further recurrences were

63 afety concerns were noted, with low rates of procedural complications and no increase in symptomatic

64 Secondary analyses included procedural complications and outcomes by clinical indica

65 The model incorporated the probability of procedural complications and recurrent symptoms necessit

66 tion, clinical failures are driven mainly by procedural complications and restenosis, but the subsequ

67 Procedural complications and treatment were noted.

68 Secondary end points included procedural complications and type 4a periprocedural myoc

69 Secondary outcomes included procedural complications and valve hemodynamics.

70 observed even in the absence of discernible procedural complications and was more common in patients

71 mortality was not directly associated with a procedural complication, and the mortality rate due to c

72 fication codes, we identified comorbidities, procedural complications, and causes of readmission foll

73 coronary lesions with high success rate, low procedural complications, and low major adverse cardiova

74 Patient factors, procedural complications, and operator experience are pr

75 mprovements in existing devices have reduced procedural complications, and scientific trials are inve

76 at transesophageal echocardiography, higher procedural complications, and similar clinical outcomes

77 There were 96 (2.94%) observed procedural complications, and the Mayo Clinic risk score

78 al success of the fiducial marker placement, procedural complications, and the surgical localization

79 Procedural complications are responsible for a small fra

80 2021 to identify original articles reporting procedural complications associated with intracoronary A

81 luded all-cause mortality at 6 months, major procedural complications, bleeding, and access-site comp

82 Apart from procedural complications, both treatments are equally ef

83 of lead extraction does not track well with procedural complications, but several small retrospectiv

84 ortic valve predilatation (BAVP) in reducing procedural complications, but there are few data to supp

85 variables were significantly correlated with procedural complications: cardiogenic shock, left main c

86 jor adverse cardiac events but lower risk of procedural complications compared with other MCS.

87 s mostly acute cardiac (52.9%, n=45), with a procedural complication composing a small fraction (7.1%

88 Procedural complications, congestive heart failure, and

89 75.1%; p < 0.001), while procedural time and procedural complications decreased.

90 The secondary end points included procedural complications, device-related thrombus, perid

91 The number of peri-procedural complications did not differ between the grou

92 Major procedural complications during PCI are infrequent, but

93 age, genetic syndrome, noncardiac diagnoses, procedural complications, extracorporeal membrane oxygen

94 Procedural complications from PFO closure occurred in 14

95 cally designed to improve closure and reduce procedural complications has now become the first-line t

96 th LEB, PVI was associated with fewer 30-day procedural complications, higher revascularization rates

97 -defibrillator (ICD) implantation volume and procedural complications in a contemporary, representati

98 Device implantation was successful without procedural complications in all patients, with significa

99 tent residual stenosis) and safety outcomes (procedural complications, in-hospital major adverse card

100 Reported procedural complications included 1 renal artery dissect

101 Procedural complications included 10 bleeding events and

102 Procedural complications included conduit rupture requir

103 Procedural complications included death in 1.4%, sustain

104 Procedural complications including THV malpositioning, s

105 but later made CMO experienced high rates of procedural complications, including cardiogenic shock (3

106 sociated with a slightly higher incidence of procedural complications, including no reflow (3.9% vers

107 Five patients had procedural complications: lead dislodgment in 4 requirin

108 example, few PCI readmissions are caused by procedural complications, limiting the extent to which i

109 Clinical outcomes included procedural complications, myocardial infarction (MI), an

110 Procedural complications occurred in 1.5% and 1.0% of pa

111 Procedural complications occurred in 12 patients (1.7%)

112 Major procedural complications occurred in 4 of the 113 patien

113 Procedural complications occurred in 5 cases (1.4%) afte

114 Procedural complications occurred in 7 patients (4.7%) i

115 Procedural complications occurred in less than 1% of the

116 Procedural complications occurred infrequently: graft pe

117 Fewer major procedural complications occurred with elective IABP ins

118 No procedural complications occurred, although one patient

119 tamponade, ventricular arrhythmia, or other procedural complications occurred.

120 No major procedural complications occurred.

121 by the development of > or = 1 in-1ab minor procedural complication (odds ratio, 2.6; P < .0001).

122 ratio, 0.4; 95% CI, 0.25-0.64; P<0.001) and procedural complications (odds ratio, 0.4; 95% CI, 0.2-0

123 The rates of procedural complications of redo-TAVR were low (coronary

124 Most cases of NSP occurred as a procedural complication or as a complication of medical

125 There were no major procedural complications or deaths.

126 concluded the procedure with no significant procedural complications or discomfort.

127 Procedural complications or electrocardiogram changes oc

128 ocedural myocardial injury in the absence of procedural complications or evidence of new myocardial i

129 ccurred in 20.3% of patients, whereas 30-day procedural complications or later nonrestenosis events o

130 No major procedural complications or morbidity occurred.

131 vents: OR, 0.81; 95% CI, 0.30-2.18; P = .68; procedural complications: OR, 0.57; 95% CI, 0.11-1.22; P

132 he 18-month cumulative mortality (P = 0.18), procedural complications (P = 0.10), hospital complicati

133 scular events (P<0.001 for trend), and acute procedural complications (P<0.001 for trend).

134 e significant decreases in the prevalence of procedural complications, particularly in the realm of a

135 ients' risk of sudden cardiac death, risk of procedural complications, quality of life, or prognosis

136 tic evaluations were associated with greater procedural complications, radiation exposure, and expend

137 However, surgery carries a significant procedural complication rate and mortality.

138 However, the procedural complication rate exceeds that of myectomy.

139 The procedural complication rate was 6.6%.

140 EBOA catheter is technically safe with a low procedural complication rate.

141 aser sheaths is highly successful with a low procedural complication rate.

142 ble mortality but discrepant length of stay, procedural complication rates and reintervention burdens

143 c obstructive CAD, without portending higher procedural complication rates and with relatively low ra

144 Procedural complication rates included 39 pericardial ta

145 Procedural complication rates overall were low (death 0.

146 Peri-procedural complication rates were low (3 stroke [1.4%],

147 unction of the index TAVR procedure with low procedural complication rates, and death and stroke rate

148 n vein grafts have been associated with high procedural complication rates, including distal emboliza

149 ioplasty has excellent early results and low procedural complication rates, long-term outcome is temp

150 Six eligibility criteria (procedural complications rates; at least 10 patients; sa

151 tamponade is a potentially life-threatening procedural complication requiring emergent reversal of a

152 namic support among TF-TAVR patients, severe procedural complications requiring conversion to open su

153 The risk of procedural complications requiring open heart surgery wa

154 However, the possibility of procedural complications such as coronary dissection, no

155 sus n=10 [15.9%]; P=0.027), driven mainly by procedural complications such as pneumothorax, major ble

156 Secondary outcomes included procedural complications such as the occurrence of pneum

157 These patients' records were searched for procedural complications, sufficiency of biopsy tissue,

158 treatment options are associated with lower procedural complications, the technical advances have ou

159 nteger risk score for estimating the risk of procedural complications using baseline, angiographic an

160 l differences between observed and predicted procedural complications using the Mayo Clinic risk scor

161 between the bicuspid and tricuspid groups in procedural complications, valve hemodynamics (aortic val

162 Secondary outcomes included procedural complications, valve hemodynamics, and qualit

163 y mortality rate directly due to AF ablation procedural complications was 0.06% (n=4).

164 Incidence of procedural complications was low and comparable in both

165 The frequency of procedural complications was similar in the foam group (

166 Safety, including bleeding events and procedural complications, was assessed.

167 Overall procedural complications were 6.5% in CB and 3.0% in PFA

168 Procedural complications were also similar (2.2% for gro

169 Procedural complications were also similar (2.8% for mul

170 Procedural complications were also similar (3.8% for mul

171 Procedural complications were as follows: emergency bypa

172 ic intracerebral hemorrhage), mortality, and procedural complications were assessed.

173 for procedural time, procedural success, and procedural complications were evident after approximatel

174 al success, procedural time, and in-hospital procedural complications were examined.

175 Procedural complications were identified in 2.7%.

176 A TA approach and major procedural complications were independently associated w

177 Procedural complications were limited to clinically unim

178 Procedural complications were limited to two patients wi

179 tium technical (96.6%) success was high, and procedural complications were low.

180 Procedural complications were more frequent in CA versus

181 No procedural complications were observed in the BS group.

182 le procedural times, and a low rate of early procedural complications were observed.

183 Procedural complications were recorded.

184 No procedural complications were reported.

185 Rates of procedural complications were similar in both genders.

186 ghly publicized manufacturer advisories, and procedural complications, which can adversely affect mor

187 equate infrastructure to cope with potential procedural complications will minimize potential patient

188 s in roughly 1 in 5 patients following a PCI procedural complication with significant hospital-level

189 Secondary end points included procedural complications within 30 days and blood pressu

190 mposite of death, thromboembolic events, and procedural complications within 7 to 90 days.

191 The Mayo clinic predictive model for procedural complications yielded excellent results when